AI-generated research brief — verify at source
MenACYW-TT Shows Comparable Safety to Licensed Meningococcal Vaccine in Infants
In a Phase III randomized trial involving 2,777 healthy infants and toddlers, MenACYW-TT produced solicited injection site reactions in 84.9% of recipients and solicited systemic reactions in 87.1%, nearly identical to rates observed with the comparator vaccine MenACWY-CRM (84.6% and 88.2%, respectively), with all serious adverse events and deaths adjudicated as unrelated to the study vaccines. The overall safety profiles of the two quadrivalent meningococcal conjugate vaccines were judged comparable across a full four-dose infant series administered alongside routine pediatric immunizations.
What Was Studied
This study examined the safety of MenACYW-TT, a quadrivalent meningococcal tetanus toxoid-conjugate vaccine, when co-administered with standard routine pediatric vaccines across a four-dose schedule (at 2, 4, 6, and 12 months of age) in healthy infants and toddlers. The central objective was to determine whether MenACYW-TT’s safety profile is comparable to that of MenACWY-CRM, a licensed quadrivalent meningococcal oligosaccharide diphtheria CRM197-conjugate vaccine, in the youngest approved age group.
How It Was Studied
This was a Phase III, randomized, active-controlled trial (NCT03673462) conducted at sites across the USA and Puerto Rico between September 2018 and March 2023. A total of 2,777 healthy participants were enrolled and randomized in a 3:1 ratio: 2,080 received MenACYW-TT and 697 received MenACWY-CRM, both given concomitantly with a broad panel of routine pediatric vaccines including DTaP5-IPV/Hib, PCV13, rotavirus, hepatitis B, MMR, and varicella vaccines. Safety was assessed through multiple endpoints: immediate unsolicited adverse events within 30 minutes post-vaccination, solicited injection site and systemic reactions within 7 days, unsolicited adverse events within 30 days, and serious adverse events (SAEs), adverse events of special interest (AESIs), and medically attended adverse events (MAAEs) throughout the full study duration.
What Was Observed
- Solicited local and systemic reactions were high in both groups and nearly equivalent. Injection site reactions were reported in 84.9% of MenACYW-TT recipients versus 84.6% of MenACWY-CRM recipients. Systemic reactions occurred in 87.1% and 88.2% of participants, respectively — differences too small to suggest a meaningful clinical distinction between the two vaccines.
- Serious adverse events occurred at a numerically higher rate in the MenACYW-TT group. SAEs were reported in 5.2% of the MenACYW-TT group compared with 3.0% in the MenACWY-CRM group. All SAEs were assessed as unrelated to the study vaccines, and the difference in rates may partly reflect the unequal group sizes inherent in a 3:1 allocation design.
- Adverse events of special interest were rare but more frequent in the MenACYW-TT arm. AESIs were recorded in 0.9% of MenACYW-TT recipients versus 0.1% of MenACWY-CRM recipients. As with SAEs, none were attributed to the study vaccines.
- Three deaths occurred during the study, all in the MenACYW-TT group, and all were determined to be unrelated to vaccination. Given the 3:1 randomization ratio and the absence of vaccine attribution, this finding does not indicate a vaccine-associated safety signal.
Why This Matters
MenACYW-TT is approved for use in infants as young as 6 weeks of age in the USA, making the safety characterization of a full infant dosing series — administered alongside a heavy concurrent vaccine schedule — directly relevant to establishing its role in routine immunization programs. This trial provides Phase III-level evidence that MenACYW-TT is well tolerated in this vulnerable age group, with a reactogenicity profile that does not appear to meaningfully differ from an established licensed comparator. The data thereby support the practical integration of MenACYW-TT into the existing infant vaccination schedule without evidence of additive harm.
How to Read This Result
While the overall safety profiles were comparable and the trial was large and well-controlled, the numerically higher rates of SAEs (5.2% vs. 3.0%) and AESIs (0.9% vs. 0.1%) in the MenACYW-TT group — even though all were deemed unrelated to vaccination — warrant acknowledgment, as the unequal group sizes and absence of formal comparative statistical testing for these endpoints mean residual uncertainty cannot be entirely dismissed.
Limitations
The abstract does not explicitly report study limitations.